Funding for this research was provided by:
Eli Lilly and Company
Received: 22 January 2021
Accepted: 4 October 2021
First Online: 23 October 2021
: Each study was conducted with informed consent, under institutional review board approval, and in accordance with the Declaration of Helsinki (ClinicalTrials.gov numbers NCT03334396 [AD1], NCT03334422 [AD2], and NCT03435081 [AD5]).
: JIS has received honoraria as a consultant and/or advisory board member for Abbvie, Afyx, Arena, Asana, Bluefin, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi; speaker for Regeneron, Sanofi; institution received grants from Galderma. AD, LS and FN are employees of Eli Lilly and Company and may hold stock and/or stock options in the company. JPT reports personal fees from Pfizer, personal fees from Eli Lilly & Co, personal fees from Abbvie, personal fees from LEO Pharma, grants and personal fees from Regeneron, grants and personal fees from Sanofi-Genzyme, outside the submitted work. GY has been on advisory boards for and received honoraria from Sanofi and Regeneron Pharmaceuticals, Inc. TREVI, Pfizer, Novartis, Eli Lilly, Kiniksa, LEO, Galderma, Kiniksa, GSK, and his research has been funded by Pfizer, Galderma, Novartis, LEO, Kinksa, Sanofi Regeneron and Sun Pharma. LFE has received honoroaria for his work as a consultant for Abbvie, Dermavant, Dermira, Leo, Eli Lilly, Novartis, Regeneron, Sanofi-Genzyme and Ortho Dermatology, been an investigator/received grants for Abbvie, Galderma Laboratories, Ortho Dermatology and Pfizer. BK reports personal fees from AbbVie, personal fees from Almirall, personal fees from Boehringer Ingelheim, grants and personal fees from Cara Therapeutics, personal fees from AstraZeneca, personal fees from Menlo Therapeutics, personal fees from Regeneron, personal fees from Sanofi Genzyme, grants and personal fees from LEO Pharma, personal fees from Trevi Therapeutics, personal fees from Daewoong, personal fees from OM Pharma, personal fees from Incyte, personal fees from Amagma, personal fees from Maruho, outside the submitted work; In addition, BK has a patent on JAK inhibitors for chronic itch pending to None. PCG and HAD report no conflict of interest. Fabio P. Nunes was an employee of Eli Lilly and Company, Indianapolis, Indiana, USA at the time of conducting this study. Currently he is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, New Jersey, USA.